Literature DB >> 23113477

Risk, responsibility, and generic drugs.

Aaron S Kesselheim1, Jerry Avorn, Jeremy A Greene.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23113477      PMCID： PMC4036072          DOI： 10.1056/NEJMp1208781

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Timing of new black box warnings and withdrawals for prescription medications.

Authors:  Karen E Lasser; Paul D Allen; Steffie J Woolhandler; David U Himmelstein; Sidney M Wolfe; David H Bor
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

2.  Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies.

Authors:  David Madigan; Daniel W Sigelman; James W Mayer; Curt D Furberg; Jerry Avorn
Journal:  Am Heart J       Date:  2012-07-03       Impact factor: 4.749

3.  Impossible? Outlawing state safety laws for generic drugs.

Authors:  Leonard H Glantz; George J Annas
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245
  3 in total
  1 in total

1.  Generic medicines and generic substitution: contrasting perspectives of stakeholders in Ireland.

Authors:  A O'Leary; C Usher; M Lynch; M Hall; L Hemeryk; S Spillane; P Gallagher; M Barry
Journal:  BMC Res Notes       Date:  2015-12-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.